The U.S. Federal Trade Commission is looking into how big pharmacy benefit managers like CVS Caremark affect pricing and patients’ access to prescription drugs at a time when costs of some medicines, even older ones like insulin, have skyrocketed, the agency said Tuesday. Read More
Canadian Financial Resources
Most Popular Articles
Investment Resources
Self Trading Resources
Buy GOLD Online